Evolving practices, treatment decisions, and unmet needs in intermediate-stage hepatocellular carcinoma: An Asia Pacific perspective

Figure 1 Barriers to multidisciplinary team access in Asia Pacific, as identified by survey responders (n = 70). Values are shown as % (n) of respondents selecting each barrier. Percentages were calculated using all survey respondents as the denominator (n = 70). Respondents could select more than one barrier. MDT: Multidisciplinary team.

Figure 2 Preferred choice of systemic therapy for combination with locoregional therapy for the treatment of intermediate-stage hepatocellular carcinoma according to Barcelona Clinic Liver Cancer stage, as identified by Asia Pacific prescribers. Values within pie charts are shown as % (n). Denominators for each pie chart are shown beside each panel: Barcelona Clinic Liver Cancer (BCLC)-B2 first line, n = 45; BCLC-B3 first line, n = 42; BCLC-B2 second line, n = 36; and BCLC-B3 second line, n = 36. BCLC: Barcelona Clinic Liver Cancer; Pem: Pembrolizumab; Atezo: Atezolizumab; bev: Bevacizumab; Durval: Durvalumab; treme: Tremelimumab.

Figure 3 Increasing role of multidisciplinary team management in the intermediate-stage hepatocellular carcinoma patient journey. BCLC: Barcelona Clinic Liver Cancer; MDT: Multidisciplinary team; TACE: Transarterial chemoembolization; LRT: Locoregional therapy; TARE: Transarterial radioembolization.